AOD-9604 / MOTs-C / TESAMORELIN

AOD 9604 is a modified version of the hGH fragment 176-191 peptide, distinguished by the presence of a di-sulfide bridge. Originally designed as a lipolytic (fat burning) compound, AOD 9604 has exhibited promising outcomes in various areas of medical research. Studies have explored its potential benefits in addressing conditions such as heart disease, osteoarthritis with a focus on cartilage repair, and metabolic syndrome.

MOTS-c, short for Mitochondrial-Derived Peptide MOTS-c, emerges as a pivotal player in promoting metabolic balance, extending longevity, enhancing performance capacity, and combating various health conditions.

Tesamorelin is a growth hormone releasing hormone (GHRH) analogue, composed of conventional GHRH with an additional trans-3-hexanoic acid group. Tesamorelin has been the subject of exploration for its potential in enhancing peripheral nerve regeneration. Additionally, it has been considered as a prospective intervention for cognitive decline or impairment.